Industry-chain Research Brief

Linyi Weikang Biological Technology Co., Ltd.: Biomedicine Little Giant Industry Chain Brief

Shandong · Biomedicine · 2026-06-13

English company profile Full Chinese report All report summaries

English Summary

Linyi Weikang Biological Technology Co., Ltd. is a China Little Giant company report summary for overseas readers. The company is associated with Shandong. The report is indexed under Biomedicine. The Chinese report was published on 2026-06-13. The summary covers company profile, product direction, industry-chain role, technology, patent/R&D signals, scale indicators and policy-material checkpoints.

Report Snapshot

CompanyLinyi Weikang Biological Technology Co., Ltd.
RegionShandong
IndustryBiomedicine
Published2026-06-13
Chinese reportOpen
CompanyLinyi Weikang Biological Technology Co., Ltd.
Region / IndustryShandong · Biomedicine
Recognition2024 6th batch
Patent signal93 patent-related records

Company and Recognition Snapshot

Linyi Weikang Biological Technology Co., Ltd. is indexed as a national-level Little Giant enterprise in Shandong. The English profile places the company under Biomedicine and records 2024 6th batch as the available recognition context.

Recognition batch2024 6th batch
RegionShandong
IndustryBiomedicine
Registered capitalRMB 80.00 million
Employee signal116 employees
Listed statusNot listed
Patent signal93 patent-related records
R&D signalR&D investment detail not published in the English dataset

Business and Industry-chain Position

Chinese public records indicate medical-device or biomedicine activity, R&D, design and engineering activity. The recorded industry-chain position is Biomedicine and medical devices / Recorded position. This places the company in a policy-relevant segment for peer comparison by region, industry and batch.

Technology, Patent and R&D Signals

The public profile records 93 patent-related records. The R&D signal is: R&D investment detail not published in the English dataset. Patent and R&D information should be read with product direction, customer evidence and chain position rather than as isolated threshold items.

Policy-material Review Points

  • Verify whether the company's main business, niche market and product evidence all point to Biomedicine.
  • Check that patent, R&D, employee and financial fields support the same core product direction.
  • Compare the company with peers in the same province, industry and recognition batch before using the profile for supplier screening or policy research.
  • Use the linked Chinese source report for original-language evidence and source links.

Original Report and Profile

For the underlying database record, open the English company profile. For full-length analysis, original-language wording and public evidence links, open the Chinese source report.

Related Search Paths